🚀 VC round data is live in beta, check it out!
Adagene Valuation Multiples
Discover revenue and EBITDA valuation multiples for Adagene and similar public comparables like Tetratherix, Shield Therapeutics, Mayne Pharma Group, Connect Biopharma and more.
Adagene Overview
About Adagene
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
Founded
2011
HQ
Employees
138
Website
Sectors
Financials (LTM)
EV
$84M
Adagene Financials
Adagene reported last 12-month revenue of —.
In the same LTM period, Adagene generated had net loss of ($34M).
Revenue (LTM)
Adagene P&L
In the most recent fiscal year, Adagene reported revenue of $103K and EBITDA of ($30M).
Adagene expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $103K | XXX | XXX | XXX |
| EBITDA | — | XXX | ($30M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (29169%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (33266%) | XXX | XXX | XXX |
| Net Profit | ($34M) | XXX | ($33M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (32386%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Adagene Stock Performance
Adagene has current market cap of $140M, and enterprise value of $84M.
Market Cap Evolution
Adagene's stock price is $2.96.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $84M | $140M | 0.0% | XXX | XXX | XXX | $-0.71 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAdagene Valuation Multiples
Adagene trades at 809.4x EV/Revenue multiple, and (2.8x) EV/EBITDA.
EV / Revenue (LTM)
Adagene Financial Valuation Multiples
As of March 18, 2026, Adagene has market cap of $140M and EV of $84M.
Equity research analysts estimate Adagene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Adagene has a P/E ratio of (4.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $140M | XXX | $140M | XXX | XXX | XXX |
| EV (current) | $84M | XXX | $84M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 809.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.8x) | XXX | XXX | XXX |
| EV/EBIT | (2.5x) | XXX | (2.4x) | XXX | XXX | XXX |
| P/E | (4.1x) | XXX | (4.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Adagene Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Adagene Margins & Growth Rates
Adagene's revenue in the last fiscal year declined by (100%).
Adagene's revenue per employee in the last FY averaged $0.0M.
Adagene Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (29169%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 112% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 7048% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 27888% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 34935% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Adagene Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Tetratherix | XXX | XXX | XXX | XXX | XXX | XXX |
| Shield Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mayne Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Connect Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Artiva Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Adagene M&A Activity
Adagene acquired XXX companies to date.
Last acquisition by Adagene was on XXXXXXXX, XXXXX. Adagene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Adagene
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAdagene Investment Activity
Adagene invested in XXX companies to date.
Adagene made its latest investment on XXXXXXXX, XXXXX. Adagene invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Adagene
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Adagene
| When was Adagene founded? | Adagene was founded in 2011. |
| Where is Adagene headquartered? | Adagene is headquartered in China. |
| How many employees does Adagene have? | As of today, Adagene has over 138 employees. |
| Who is the CEO of Adagene? | Adagene's CEO is Peter Luo. |
| Is Adagene publicly listed? | Yes, Adagene is a public company listed on Nasdaq. |
| What is the stock symbol of Adagene? | Adagene trades under ADAG ticker. |
| When did Adagene go public? | Adagene went public in 2021. |
| Who are competitors of Adagene? | Adagene main competitors are Tetratherix, Shield Therapeutics, Mayne Pharma Group, Connect Biopharma. |
| What is the current market cap of Adagene? | Adagene's current market cap is $140M. |
| What is the current revenue growth of Adagene? | Adagene revenue growth (vs. last FY) is (100%). |
| What is the current EV/Revenue multiple of Adagene? | Current revenue multiple of Adagene is 809.4x. |
| Is Adagene profitable? | No, Adagene is not profitable. |
| What is the current net income of Adagene? | Adagene's last 12 months net income is ($34M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.